Other languages Apogee Therapeutics, Inc.

Equities

APGE

US03770N1019

Market Closed - Nasdaq Other stock markets 01:30:00 24/05/2024 am IST			5-day change	1st Jan Change
46.04 ^USD	-3.82%		-14.34%	+64.78%

15/05	Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases	CI
13/05	Apogee Therapeutics' Q1 Net Loss Widens	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases	16/05
Apogee Therapeutics' Q1 Net Loss Widens	13/05
Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease and Other Inflammatory Diseases	25/03
Apogee Therapeutics Prices Upsized $420 Million Share Offering	08/03
Sector Update: Health Care Stocks Advance Wednesday Afternoon	07/03
Apogee Therapeutics Shares Rise After Jefferies Raises Price Target	06/03
Apogee Therapeutics Unveils $350 Million Share Offering	06/03
Sector Update: Health Care Stocks Retreating Late Afternoon	06/03
Sector Update: Health Care Stocks Lower Tuesday Afternoon	06/03
Top Midday Gainers	06/03
Sector Update: Health Care	06/03
Apogee Therapeutics Shares Surge After Phase 1 Atopic Dermatitis Trial Data, Wedbush Price Target Raise	05/03
Apogee Therapeutics Says Phase 1 Study of Atopic Dermatitis Drug Candidate Exceeds Objectives	05/03
Apogee Therapeutics' Q4 Net Loss Widens	05/03
Apogee Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Apogee Therapeutics, Inc. Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases	05/03
Apogee Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Apogee Therapeutics, Inc. and Paragon Therapeutics, Inc. Announce Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology Congress	27/23/27
Apogee Therapeutics' Q2 Net Loss Widens	29/23/29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Apogee Therapeutics, Inc.

Equities

APGE

US03770N1019

Other languages

Filters